HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial.

AbstractOBJECTIVE:
To evaluate effects of preoperative high-dose glucocorticoid on the inflammatory response and recovery after endovascular aortic aneurysm repair (EVAR).
BACKGROUND:
The postimplantation syndrome after EVAR may delay recovery due to the release of proinflammatory mediators. Glucocorticoids may reduce postoperative inflammatory responses and enhance recovery, but with limited information on EVAR.
METHODS:
A single-center, randomized, double-blind, placebo-controlled trial of 153 patients undergoing elective EVAR between November 2009 and January 2013. Patients received 30 mg/kg of methylprednisolone (MP) (n = 77) or placebo (n = 76) preoperatively. Primary outcome was a modified version of the systemic inflammatory response syndrome. Secondary outcome measures were the effect on inflammatory biomarkers, morbidity, and time to meet discharge criteria.
RESULTS:
Of 153 randomized patients, 150 (98%) were evaluated for the primary outcome. MP reduced systemic inflammatory response syndrome from 92% to 27% (P < 0.0001) (number needed to treat = 1.5), maximal plasma interleukin 6 from 186 pg/mL [interquartile range (IQR) = 113-261 pg/mL] to 20 pg/mL (IQR = 11-28 pg/mL) (P < 0.001) and fulfillment of discharge criteria was shorter [2 days (IQR = 2-4 days) vs 3 days (IQR = 3-4 days)] (P < 0.001). C-reactive protein, temperature, interleukin 8, and soluble tumor necrosis factor receptor were also reduced (P < 0.001) by MP. Myeloperoxidase, D-dimer, and matrix metalloproteinase 9 were not modified. No differences in 30-day medical (23% vs 36%) (P = 0.1) or surgical (20% vs 21%) morbidity were found in the active group versus the placebo group.
CONCLUSIONS:
Preoperative MP attenuates the inflammatory response with a faster recovery after EVAR for abdominal aortic aneurysms. Further safety and dose-response studies are required to allow recommendations for general practice.
TRIAL REGISTRATION:
clinicaltrials.gov Identifier: NCT00989729.
AuthorsLouise de la Motte, Henrik Kehlet, Katja Vogt, Claus H Nielsen, John B Groenvall, Henning B Nielsen, Andreas Andersen, Torben V Schroeder, Lars Lönn
JournalAnnals of surgery (Ann Surg) Vol. 260 Issue 3 Pg. 540-8; discussion 548-9 (Sep 2014) ISSN: 1528-1140 [Electronic] United States
PMID25115430 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Glucocorticoids
  • Interleukins
  • Methylprednisolone
Topics
  • Aged
  • Aortic Aneurysm, Abdominal (surgery)
  • Area Under Curve
  • Blood Vessel Prosthesis Implantation
  • Double-Blind Method
  • Endovascular Procedures
  • Female
  • Glucocorticoids (administration & dosage, therapeutic use)
  • Humans
  • Interleukins (blood)
  • Length of Stay
  • Male
  • Methylprednisolone (administration & dosage, therapeutic use)
  • Postoperative Complications (prevention & control)
  • Preoperative Period
  • Systemic Inflammatory Response Syndrome (prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: